January 30, 2019 News by Jonathan Grinstein Canadian RRMS Patients Less Likely to Discontinue Treatment with Oral Gilenya, Compared to Injectable or Infusible Therapies Multiple sclerosisĀ (MS) patients in Canada are more likely to comply with their treatment plan and less likely to discontinue the use of the oral disease-modifying treatment Gilenya (fingolimod), compared to injectable or infusible treatment options, new research shows. The research article with that finding, āA…
July 30, 2018 News by Jose Marques Lopes, PhD African-Americans Show Better Adherence and Satisfaction with Gilenya Than Injectable DMTs, Phase 4 Study Finds African-Americans with relapsingāremitting multiple sclerosis (RRMS) show higher adherence and greater satisfaction when treated with oralĀ Gilenya (fingolimod, by Novartis) than with injectable therapies, according to a new study. The research, āTreatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A…
January 11, 2018 News by Patricia Silva, PhD Newly Diagnosed MS Patients Stay Longer on Rituxan Than Other Therapies, Study Finds Multiple sclerosis patients whose first treatment is Genentech'sĀ Rituxan (rituximab) stay on it longer than other disease-modifying drugs that patients start with, a Swedish study reports. When they stop taking Rituxan, Ā it usually isn't for lack of effectiveness or side effects...
November 16, 2016 Columns by Judy Lynn Do MS Injectable Medications Need Refrigeration? Traveling with multiple sclerosis (MS) is challenging for a number of reasons. There are many symptoms a person may need to consider, such as accessibility, temperature control, and medication management, to name a few.Ā While packing for a recent extended trip, I realized that my one-week pill box wasnāt…
November 9, 2016 Columns by Judy Lynn MS Needle Fatigue: That Sudden, ‘I Am Not an Orange’ Feeling āI can come over and stab you, if Gramma canāt do it,ā read the Facebook post from my oldest son.Ā āAw ā¦ thanks, kiddo,ā I replied. Some things seem more interesting when taken out of context!Ā Of course, most of you will realize that my son was offering to…
June 8, 2015 News by Patricia Silva, PhD Review Suggests PEG-IFN Therapy for Relapsing-Remitting Multiple Sclerosis Significantly Reduces Relapse Rates A study recently published in the journal PLoS One compared the use of a specific treatment based on interferon beta-1a with other approved injectable therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The study is entitled āA Network Meta-Analysis of Efficacy and Evaluation of…